title: Drug interactions with new and investigational antiretrovirals.
abstract: More than 20 individual and fixed-dose combinations of antiretrovirals are approved for the treatment of human immunodeficiency virus (HIV) infection. However, owing to the ongoing limitations of drug resistance and adverse effects, new treatment options are still required. A number of promising new agents in existing or new drug classes are in development or have recently been approved by the US FDA. Since these agents will be used in combination with other new and existing antiretrovirals, understanding the potential for drug interactions between these compounds is critical to their appropriate use. This article summarizes the drug interaction potential of new and investigational protease inhibitors (darunavir), non-nucleoside reverse transcriptase inhibitors (etravirine and rilpivirine), chemokine receptor antagonists (maraviroc, vicriviroc and INCB 9471), integrase inhibitors (raltegravir and elvitegravir) and maturation inhibitors (bevirimat).
authors.affiliation: School of Pharmacy, Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Brown
authors.forename: Sunita
authors.initials: S
authors.lastname: Paul
authors.forename: Angela D M
authors.initials: AD
authors.lastname: Kashuba
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D006801:Humans; D015394:Molecular Structure; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D013386:Succinates / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D014315:Triterpenes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D053978:Pentacyclic Triterpenes
chemical_list: D019380:Anti-HIV Agents; D015507:Drugs, Investigational; D019428:HIV Integrase Inhibitors; D017320:HIV Protease Inhibitors; D019707:Receptors, Chemokine; D018894:Reverse Transcriptase Inhibitors; D013386:Succinates; D014315:Triterpenes; C479935:bevirimat; D053978:Pentacyclic Triterpenes